Innate Pharma (IPHYF) Receivables (2017 - 2025)

Innate Pharma's Receivables history spans 9 years, with the latest figure at $15.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 184.46% year-over-year to $15.4 million; the TTM value through Dec 2025 reached $15.4 million, up 184.46%, while the annual FY2025 figure was $15.4 million, 180.85% up from the prior year.
  • Receivables reached $15.4 million in Q4 2025 per IPHYF's latest filing, up from $5.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $71.2 million in Q4 2023 to a low of $5.4 million in Q4 2024.
  • Average Receivables over 5 years is $37.5 million, with a median of $39.2 million recorded in 2022.
  • Peak YoY movement for Receivables: tumbled 92.41% in 2024, then surged 184.46% in 2025.
  • A 5-year view of Receivables shows it stood at $56.1 million in 2021, then plummeted by 30.17% to $39.2 million in 2022, then skyrocketed by 81.81% to $71.2 million in 2023, then crashed by 92.41% to $5.4 million in 2024, then soared by 184.46% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Receivables are $15.4 million (Q4 2025), $5.4 million (Q4 2024), and $71.2 million (Q4 2023).